Treatment of relapse of hematological malignancies following allogeneic hematopoietic SCT (allo-HSCT) remains very challenging and relies usually on the readministration of chemotherapy combined with donor lymphocyte infusion (DLI). To enhance DLI effectiveness, lymphodepletion (LD) with fludarabine (Flu) and/or CY before the injection of lymphocytes is an attractive modality to modify the immune environment, leading possibly to suppression of regulatory T cells (T reg ) and exposing the patient to cytokine activation. However, LD before DLI may lead to induction of deleterious GVHD. To avoid inducing overwhelming toxicity, we proceeded by escalating doses of both LD and DLI. Eighteen patients with various non-CML hematological malignancies who relapsed following allo-HSCT were treated with chemotherapy and LD-DLI or LD-DLI upfront. T-cell subpopulation and DC levels as well as cytokine plasma levels (IL-7, IL-15) were measured before and following LD-DLI. Cumulative incidence of acute grade II --IV GVHD was 29.4% similar to that reported in patients receiving DLI without LD. In addition, Flu alone with low dose of DLI was not associated with severe GHVD. CY/Flu at the respective doses of 600 mg/m 2 on day 1 and Flu 25 mg/m 2 /day on days 1 --3 did not result in a marked decrease of T reg cells, nor in endogenous IL-7 and IL-15 production. However, a peripheral expansion of DCs was observed. These findings suggest that the escalated dose procedure appears safe and prevent overwhelming toxicity. A dose-limiting toxicity has not yet been reached.
INTRODUCTION
Relapse of hematological malignancies following allogeneic hematopoietic SCT (allo-HSCT) remains a major cause of treatment failure. 1, 2 There is a large body of evidence indicating that the curative effect of allo-HSCT depends upon the induction of an immune-mediated graft-versus-tumor response. In relapsed CML, donor lymphocyte infusion (DLI) can lead to a significant and durable response rate. 3 --6 For non-CML diseases, however, DLI remains relatively disappointing. 7, 8 Retreatment with chemotherapy might be required before reusing cell therapy with DLI. Lymphodepletion (LD) may enhance the anti-tumor effects of transferred T cells in vivo through several mechanisms, including the elimination of the so-called suppressive CD4 þ CD25 þ regulatory T cells (T reg ), natural killer T cells, and creation of an immunological 'space' with recruitment of homeostatic proliferative cytokines such as IL-7 and IL-15. 9,10 Also, prior host LD proved to be critical for the anti-tumor efficacy of adoptive therapy with DLI. 11, 12 Thus, DLI efficacy might be improved through manipulation of the recipient immune environment to allow for in vivo expansion of donor T cells. Miller et al. 13 assessed the potential impact of prior LD with fludarabine (Flu) and CY followed by a fixed high dose of DLI. The latter strategy allowed for increased T-cell proliferation, but was associated with a high incidence of severe acute GVHD. With this background, we postulated that induction of a relatively 'milder' lymphopenia in a graduated manner may reduce toxicity, whilst still allowing for better availability of in vivo homeostatic cytokines to the benefit of transferred T cells. The present pilot trial was designed as a doseescalation study of DLI preceded by LD with Flu and Cy.
PATIENTS AND METHODS

Study design
This was a prospective pilot study that included 18 consecutive adult patients (7 males) treated in a single institution (CHU de Nantes, Nantes, France) between January 2008 and July 2010. The hypothesis was that an escalated dose of chemotherapy-induced lymphodepletion will enhance DLI efficacy without increasing the incidence or severity of GVHD. The study inclusion criterion was overt relapse of any hematologic malignancy following allo-HSCT irrespective of the type of donor, stem cell source or type of conditioning regimen. Data were updated as of 15 June 2011. Patients were fully informed of the treatment and had provided informed consent. The study was conducted according to institutional guidelines.
Patients and treatment
Patient characteristics and treatment history are summarized in Table 1 . The median age at time of allo-HSCT was 45 (range, 18 --67) years. This series included various relapsed non-CML hematological malignancies: six AMLs/myelodysplatic syndromes (MDS), five ALL, three Hodgkin's diseases (HD), two T-cell non-Hodgkin's lymphomas (T-NHL) and two multiple myelomas (MM). The allo-HSCT procedure consisted of a myeloablative conditioning regimen in six patients and a reduced-intensity conditioning (RIC) in the remaining twelve cases. Ten donors were HLA-identical siblings and eight were HLA-matched unrelated (MUD; 10/10 at the allelic level).
To avoid overwhelming toxicity resulting from severe GVHD as described by Miller et al., 13 we opted to sequentially escalate LD and the T-cell doses infused within the DLI. Dose escalation occurred within each patient. In the first step, the LD process consisted of Flu 25 mg/m 2 /day for 3 days followed by infusion of 1 Â 10 7 CD3 þ T cells/kg recipient body weight. In the absence of development of GVHD and with disease either persisting or progressing, the same LD schedule was followed by a second DLI at 5 Â 10 7 CD3 þ T cells/kg. At the next step, LD combined both Cy 600 mg/m 2 for one day and Flu 25 mg/m 2 /day for 3 days followed by DLI at 5 Â 10 7 CD3 þ cells/kg. The plan was to enroll at least 4 patients at each dose level, then the next higher chemotherapy or cell dose level was administered to the patient if required and if no GVHD beyond grade II or other toxicities had occurred.
Immunomonitoring following DLI
Blood was collected and diluted in PBS overlaid onto Ficoll-Histopaque and centrifuged 30 min at 400 g and 20 1C, PBMC fraction was collected, washed in PBS, counted, aliquoted and frozen at À80 1C in 90% FCS/10% DMSO. T-cell subpopulations were quantified by flow cytometry using FACScanto II with DIVA software (BD Biosciences, Le Pont de Claix, France). For detection of T reg cells, PBMCs were first incubated with antibodies against CD3 (APC-H7, BD Biosciences), CD4-Pacific Blue, CD25-PE (both from Biolegend, Ozyme, SaintQuentin-en-Yvelines, France). Surface-stained PBMCs were fixed and permeabilized using fixation and permeabilization buffer (eBiosciences, Paris, France) and incubated with Alexa-647-conjugated Foxp3 (Biolegend). T-cell subpopulations were detected by multi-color staining using conjugated monoclonal antibodies against CD3-APC-H7 (BD Bioscience), CD4-PECg7, CD8 Pacific Blue, CD45RA-APC, CD27-FITC (all from Biolegend). For detection of plasmacytoid DCs and myeloid DCs, PBMCs were stained with FITC conjugated lineage markers (lin, BD Bioscience), BDCA-PE, CD11c-APC (both from Myltenyi Biotec, Paris, France), CD123-PECg7 and HLA-DR APC-Cg7 (from Biolegend).
Plasma cytokine levels
Plasma samples were drawn before the first LD immediately before the DLI and time point 14 days after DLI. Plasma samples were frozen, thawed and analyzed simultaneously using a commercial ELISA kit. This assay was capable of detecting at least 0.4 pg/mL of IL-7 (Diaclone, Besanc¸on, France) and IL-15 (BD Biosciences).
Statistical analysis
OS was estimated from the date of the first LD-DLI using the Kaplan --Meier method. Pre-and post-DLI absolute numbers of the different immune cells were compared using the paired t-tests and were considered statistically significant if the P value was p0.05.
RESULTS
LD-DLI and GVHD
Among patients included in this study, relapse occurred at a median of 3.8 months (1.5 --175) following allo-HSCT. None of the 18 patients had signs of acute or chronic GVHD at time of DLI. Five of seven male recipients had a female donor. Different salvage therapies were proposed prior LD-DLI for 14 patients (Table 1) : either standard 'unmanipulated' DLI alone (one AML, one HD) or DLI combined chemotherapy (two AML, three ALL, two MM, one T-NHL) or chemotherapy alone (two ALL, one HD, AML). Four patients received LD-DLI up-front as salvage therapy. Chemotherapy included dasatinib for a Ph-positive ALL, asparaginase for another case of ALL, nelarabine and vinblastine-prednisone for one ALL, VCR and dexamethasone for the remaining two ALL, bortezomib and lenalidomide-prednisone for the two myeloma cases, azacitidine for one AML, high dose aracytine for another case of AML, aracytine and amsacrine for the remaining case of AML, alemtuzumab for one T-NHL, mechlorethamine, vincristine, procarbazine, prednisone (MOPP) and vinblastine for one HD. Among the 14 patients who received salvage chemotherapy prior DLI, only three (two AML, one MM) were in CR when they received DLI. As the primary aim of study was to assess the impact of LD-DLI, different salvage chemotherapies were used and adapted to the different disease entities.
Overall, 44 DLI procedures were performed, including 28 LD-DLIs. Ten, six and two patients received, respectively, one, two and three LD-DLIs. The first LD-DLI was given at a median of 8 (range, 2 --179) months following allo-HSCT and 3.3 (range, 0.7 --14.7) months after relapse. For those who received chemotherapy prior to LD-DLI, the time between the last chemotherapy and first LD-DLI was 32 days (range 7 --60). Immune suppression was discontinued in all cases for a median of 105 days (range 11 days --175 months) at the time of DLI. Patients were treated in cohorts of dose-escalated LD and increasing dose of DLI (Figure 1 ). The first cohort (n ¼ 5) included patients receiving LD by Flu alone 25 mg/m 2 /day Â 3 followed by DLI at progressive doses (Figure 1a) . In this cohort, no severe toxicity was observed. In the second cohort (n ¼ 4), following a first LD-DLI with Flu alone, CY was introduced in combination with Flu before DLI (Figure 1b) . In this second cohort, 2 patients developed GVHD: one case of cutaneous grade 2 and another case with cutaneous grade 3, liver grade 3 and gut grade 4. The third cohort from this series (n ¼ 5) included patients who had received prior DLI without LD and were subsequently treated with LD combining both Flu and CY followed by high-dose (5 Â 10 7 CD3
þ T cells/kg) DLI (Figure 1c ). In this latter cohort, only one patient developed a cutaneous grade 3 GVHD. The fourth and last cohort (n ¼ 4) included patients who had not received previous DLI, during their disease history, before receiving LD with Flu and CY followed by high dose DLI (Figure 1d ). In this last group, one case of gut grade 4 acute GVHD was observed.
In the whole study group, the cumulative incidence of grade 2 --4 acute GVHD was 29.4% ( Figure 2 ) with a median onset of GVHD of 31 (range, 15 --59) days following the last LD-DLI. Two patients developed grade 4 acute GVHD. One of the latter cases of acute GVHD progressed into extensive chronic GVHD and the other patient died from lung cancer. Three of sixteen evaluable patients developed extensive chronic GVHD.
Immunomonitoring following LD-DLI The absolute numbers of leukocytes, lymphocytes and DCs were measured before and following LD-DLI for eight patients. LD for those patients consisted of Flu and CY (Figure 3 ). There was no statistically significant change of the absolute number of (Figure 3d ) decreased, whereas the number of circulating CD11c þ (myeloid) DCs increased, without reaching statistical significance. In contrast, BDCA2 þ (plasmacytoid) DCs raised significantly (Figure 3h ). We were unable to observe any increase of IL-7, IL-15 level at day-14 post DLI.
Disease response and survival In this study, DLI was either the first relapse treatment or given following salvage chemotherapy as detailed above. After salvage chemotherapy, three patients were in CR (two AML, one MM). Following LD-DLI, four additional patients achieved a CR (one AML, two ALL and one T-NHL).
The three patients who were in CR prior DLI, remained in CR for 4.4, 6.4 and 7.5 months following the first LD-DLI, but they all subsequently relapsed. Among the other four additional patients who achieved a CR after LD-DLI, two patients showed extramedullary relapse at 22 and 14 months following the first LD-DLI. Both patients had developed chronic extensive GVHD. In terms of chimerism status, five patients out of eight who had a mixed donor chimerism before DLI, converted to full donor chimerism. Chimerism analyses were not performed for the remaining three other patients.
With a median follow-up of 12 (range 2 --40) months from the first LD-DLI, six patients (three HD, one ALL, one AML, one MM) are still alive, of whom only one remaining in CR at 27 months from the first LD-DLI (one ALL). Ten patients died because of disease progression (nine because of their original malignancy and one from lung cancer while responding to DLI). The OS was 39% (95% CI, 18 --59%) at 2 years and 29% at 3 years (95% CI, 9 --53%) (Figure 4 ).
DISCUSSION
Treatment of relapse of hematological malignancies other than CML following allogeneic HSCT remains a difficult challenge and the prognosis following relapse is usually very poor. As a result, despite the risk of severe GVHD, DLI is widely accepted as a valid approach in this setting. 2 However, DLI proved to be ineffective in many cases for several reasons. Either the tumor burden is too high and disease progression is too overwhelming or malignant cells develop strategies to escape the immune system such as Figure 3 . Absolute counts before LD with Flu and CY (n ¼ 6), on the day of DLI and 14 days following DLI of lymphocytes (a), CD4
þ (myeloid) DCs (g) and plasmacytoid DCs (h). The only significant modification observed was the increase of plasmacytoid DCs (P ¼ 0.035). downregulation of co-stimulatory molecules. 14 Additional factors may have a role in explaining tumor evasion. 4 Strategies to enhance the anti-tumor activity of the infused donor T cells have been developed, including the injection of IL-2, 15 and the ex vivo expansion or activation of T cells. 16 The adoptive transfer of ex vivo expanded CD8 þ cytotoxic T cells that recognize specifically recipient mHAgs for leukemic relapse, reported by Warren et al., 17 resulted in complete but transient remission. In this latter trial, however, the patients experienced severe pulmonary toxicity following CTL infusion because of mHAg gene expression in lung tissue.
On the other hand, a lymphopenic environment may contribute to improving the persistence of transferred T cells by a resultant reduction in competition for cytokines, increased available space for lymphocytes and eliminating or reducing CD4 þ CD25 þ regulatory cells or other cells with suppressive function. Indeed, evidence exists in murine preclinical models supporting the notion that induction of immune lymphodepletion in the recipient by non-myeloablative irradiation or chemotherapy, such as CY before adoptive transfer of T cells can markedly improve survival in tumor bearing mice. 18 --20 This may be due to several mechanisms: CY can cause immunosuppression when used at high dosage, whereas low doses can enhance immune reponses. 21 It can also decrease the number of CD4 þ CD25 þ T reg cells in tumor-bearing rats 22 as CD4 þ CD25 þ cells are more sensitive to CY, 23 --26 inducing apoptosis and interfering with CD4 þ CD25 þ T reg -induced homeostasis. 27 In the human setting, Dudley et al. 28, 29 were the first to demonstrate that LD with CY (60 mg/kg/day Â 2 days) combined with Flu (25 mg/m 2 /day Â 5 days) can modify the host environment to allow in vivo expansion of melanoma-specific T cytotoxic lymphocytes.
Miller et al. 13 pioneered the LD approach in the context of DLI after allo-HSCT. Combining Flu and CY at high dosage followed by the infusion of a fixed dose of 1 Â 10 8 CD3 þ cells/kg, they observed a high incidence of severe acute GVHD (cumulative incidence of grade 2 to 4 GVHD, 60%). The dosage of CY they used 50 mg/kg corresponded approximatively to 2000 mg/m 2 , a dose of CY three times higher than the one we used in our highest cohort level of LD. With Flu alone used for LD, we did not observe severe acute GVHD. Increased incidence of more significant GVHD only started to be seen when CY was added suggesting a marginal role for fludarabine alone in LD.
Recently, T reg -depleted DLI have been used to induce alloreactivity with the hope of eliciting a graft-versus-tumor effect in relapsing patients. 30 These data suggested that GVHD induction through T reg depletion may improve survival. However, additional LD with CY and Flu was further required for some patients to elicit GVHD. In addition, one should bear in mind that depletion of T reg cells might be of short efficacy because conversion of naïve T cells into T reg may replenish or expand pool of T reg cells. 31 Therefore T reg inhibition may prove to be a preferable option in order to avoid a wave of peripheral converted T reg cells, especially that chemotherapy-based LD can induce a rapid activation of DCs as shown in murine models. 32 --34 In our series, we observed a trend toward increased numbers of myeloid DCs and a significant raise of plasmacytoid DCs (PDC). This increase might be mediated through the modulation of hematopoietic factors namely Flt3 ligand following chemotherapy. 34 However, we did not observe significant decrease in the number of T reg cells 14 days following DLI in those few patients who received both Flu and CY prior DLI indicating that Treg lymphodepletion was not completely achieved. This might be due to the relatively low number or inappropriate timing of analyzed samples, or to the low dosage of CY that is reflected clinically by the absence of severe GVHD. Similarly, there was no increase of serum levels of IL-7 and IL-15. Progressive increase of CY might further enhance LD.
The significance of the present study lies in the fact that, although up-front administration of large doses of DLI may be complicated by a high incidence of acute GVHD, 7, 35 we showed that an escalating dose approach of both LD and DLI can not only prevent excessive toxicity but also results in induction of CR in some patients. Of the cytotoxic agents, CY rather than Flu appears to be the active drug in inducing LD before DLI. On the basis of these results and because a dose-limiting toxicity has not been observed thus far, we are currently examining in a more homogeneous group of patients further increases of the CY dose alone to obtain higher level of LD while closely monitoring GVHD incidence and severity, modifications of T-cell subsets and DCs, and levels of homeostatic cytokines. In case of high-risk disease, preemptive LD-DLI might also be considered.
